Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in Young Children with and without Prior Nevirapine Exposure for the Prevention of Mother-To-Child HIV Transmission

摘要

BackgroundIn a randomized trial comparing nevirapine (NVP)- versus lopinavir/ritonavir (LPV/r)– based antiretroviral therapy (ART) in HIV-infected children (primary endpoint discontinuation of study treatment for any reason or virologic failure (VF) by week 24) aged two months to three years, we assessed whether clinical, virologic, immunologic and safety outcomes varied by prior single-dose NVP exposure (PrNVP) for prevention of mother-to-child HIV transmission and other covariates.